U.S., Dec. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07262333) titled 'A Trial of Hydroxynidone Capsules in Single-dose Administration for Patients With Renal Insufficiency' on Nov. 17.
Brief Summary: Hydronidone capsules are pyridinone-based small molecule compounds. Hydronidone has not been approved for commercial sale both domestically and internationally. The applicant has completed the preliminary Phase I and Phase II clinical trials. The results showed that Hydronidone is a safe and effective drug for treating liver fibrosis in chronic hepatitis B, and it has good safety and tolerability.
Based on the preliminary clinical research, a special population study has been initiated. The aim is to inve...